Amyotrophic lateral sclerosis

Recent articles

Research image of brain cells involved with Amyotrophic lateral sclerosis (ALS) illuminated through genetic tools

Allen Institute sets sights on treatments for five brain diseases

The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.

By Calli McMurray
2 June 2026 | 5 min read

Expanding set of viral tools targets almost any brain cell type

Harmless viruses that encase short noncoding DNA elements called enhancers enable cell-type-specific gene delivery across the central nervous system in rodents and primates.

By Holly Barker
19 November 2024 | 2 min watch
Abstract illustration of antibodies scattered against a peach-colored background.

We found a major flaw in a scientific reagent used in thousands of neuroscience experiments — and we’re trying to fix it.

As part of that ambition, we launched a public-private partnership to systematically evaluate antibodies used to study neurological disease, and we plan to make all the data freely available.

By Mona AlQazzaz, Aled Edwards
5 February 2024 | 6 min read

Explore more from The Transmitter

Mayank Chugh headshot photo illustration collage.

Training graduate students as a teaching professor

Mayank Chugh instructs graduate students in a range of molecular biology techniques at the University of Maryland and carves out time to do metascience research as well.

By Katie Moisse
20 November 2026 | 7 min read
Research image of neuronal stress.

Loss of Angelman-linked UBE3A gene triggers stress response in neurons

A failure to break down asparagine synthetase ultimately leads to stunted neuronal development.

By Sarah Thau
19 November 2026 | 4 min read

What makes computation possible in brains?

Nima Dehghani formalizes how computation can arise out of physical systems, such as brains, and describes the “special sauce” for real biological agency.

By Paul Middlebrooks
18 November 2026 | 1 min read